Valvular heart disease caused by Chinese proprietary slimming medicine adulterated with fenfluramine

Hong Kong Journal of Paediatrics

Volumn 10, Issue 1, 2005, Pages

  Chang, K ^a   Mak, T W L ^a   Kwong, L ^a   So, K T ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Appetite depressants; Chinese medicine; Fenfluramine; Heart valve diseases

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; HERBACEOUS AGENT; SEVEN DAYS SEVEN FAIRY MAIDENS FOREVER YOUTH IMMUNITY CAPSULE;

ADOLESCENT; AORTA VALVE REGURGITATION; ARTICLE; CASE REPORT; CHINESE MEDICINE; CLINICAL FEATURE; DIET; DIZZINESS; DRUG CLASSIFICATION; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART PALPITATION; HONG KONG; HUMAN; MITRAL VALVE REGURGITATION; PHYSICAL EXAMINATION; THORAX RADIOGRAPHY; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 19744383538     PISSN: 10139923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. FDA announces withdrawal of fenfluramine and dexfenfluramine. Available at: www.fda.gov/cder/news/fenphenpr81597.htm. (Last accessed in July 2003).
2. Wang Q, Tse HF, Yu CM, IP Mary, Lau CP. Valvular Heart Disease Associated with Anorectic Drugs. J HK Coll Cardiol 1998;6:20-3.
3. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol 1999;24:745-92.
4. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
5. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143-8.
6. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
7. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
8. Anonymous. FDA Analysis of Cardiac Valvular Dysfunction with Use of Appetite Suppressants. Available at www.fda.gov/cder/news/fenphendate.pdf (Accessed in March 2003).
9. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
10. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
11. Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis 1983;127:747-50.
12. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-6.
13. Department of Health Announces Withdrawal of Fenfluramine-Fenfluramine Reminder. Available at: www.info.gov.hk/dh/ useful/ltod/fenfluramine.htm. (Last accessed in July, 2003).